Danaher Corp
DHR: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$924.00 | Shvznl | Qvqvtwzt |
Danaher Earnings: Bioprocessing Unit May Be Bottoming Amid Veralto Spinoff
Narrow-moat Danaher turned in solid third-quarter results, as its bioprocessing business appears to be bottoming near management expectations. At first blush, we do not anticipate changing near-term expectations or our $243 fair value estimate materially, which incorporates the Veralto spinoff. Danaher's shares remain moderately undervalued.